Salvage Surgery for Metastatic Gall Bladder Cancer with Vanishing Liver Metastasis Following Palliative 5-Fluorouracil Metronomic Chemotherapy

• Main Authors: RDR Somasekar, Obla Naganathbabu, Raju Prabhakaran, Murugaiyan Gnanasekar, Devy Gounder Kannan
• Format: Article
• Language: English
• Published: JCDR Research and Publications Private Limited 2017-05-01
• Series: Journal of Clinical and Diagnostic Research
• Subjects: biliary tract cancer; cholecystectomy; low dose chemotherapy; tumour biology
• Online Access: https://jcdr.net/articles/PDF/9938/26460_CE(RA1)_F(T)_PF1(P_PG)_PFA(PG_SS).pdf
• ISSN: 2249-782X; 0973-709X

Gall Bladder Cancer (GBC) is an aggressive malignancy. The prognosis of metastatic GBC is dismal. Until recently, there are no standard treatment guidelines for management of patients with metastatic GBC. But the ultimate aim of any treatment modality is to improve the overall survival with good quality of life. We hereby report a long term survivor of metastatic GBC treated with initial six cycles of gemcitabine + cisplatin combination chemotherapy, but did not show any response. In view of chemotoxicity and as a matter of physician preference patient was started on low dose weekly 5- Fluorouracil monotherapy based on a metronomic chemotherapy principle. There was complete resolution of all the liver metastasis and salvage radical cholecystectomy was done. The patient is disease free on imaging at eight months of follow up. A very few such cases have been reported in the world literature, till date. Metastatic disease must not be considered incurable as there are no objective measures to predict tumour biology. Further research on metronomic chemotherapy and tumour genetics in such patients will open a new era of individualised cancer therapy based on objective measures that will predict tumour biology.